Brief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
21/09/2026 21:19
BRIEF-Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026 Sept 22 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O:
INSIGHT MOLECULAR DIAGNOSTICS - ENTERS AMENDMENT NO. 2 TO MERGER AGREEMENT ON SEPT 15, 2026 - SEC FILING
INSIGHT MOLECULAR DIAGNOSTICS - CHRONIX EQUITY HOLDERS TO RECEIVE 10% ROYALTY FOR SALES OF CNI MONITOR - SEC FILING
Further company coverage: IMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission